PT915697E - Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade - Google Patents

Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade

Info

Publication number
PT915697E
PT915697E PT97936939T PT97936939T PT915697E PT 915697 E PT915697 E PT 915697E PT 97936939 T PT97936939 T PT 97936939T PT 97936939 T PT97936939 T PT 97936939T PT 915697 E PT915697 E PT 915697E
Authority
PT
Portugal
Prior art keywords
vulsioners
uteis
sulfamate
obesity
derived
Prior art date
Application number
PT97936939T
Other languages
English (en)
Portuguese (pt)
Inventor
Richard P Shank
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT915697(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of PT915697E publication Critical patent/PT915697E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
PT97936939T 1996-06-28 1997-06-23 Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade PT915697E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2200496P 1996-06-28 1996-06-28

Publications (1)

Publication Number Publication Date
PT915697E true PT915697E (pt) 2003-02-28

Family

ID=21807338

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97936939T PT915697E (pt) 1996-06-28 1997-06-23 Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade

Country Status (23)

Country Link
US (1) US6071537A (enExample)
EP (1) EP0915697B1 (enExample)
JP (1) JP2000514425A (enExample)
CN (1) CN1106193C (enExample)
AP (1) AP1285A (enExample)
AT (1) ATE224189T1 (enExample)
AU (1) AU732923B2 (enExample)
BR (1) BR9710994A (enExample)
CA (1) CA2258893C (enExample)
CZ (1) CZ293876B6 (enExample)
DE (1) DE69715631T2 (enExample)
DK (1) DK0915697T3 (enExample)
ES (1) ES2184127T3 (enExample)
HU (1) HU226775B1 (enExample)
IL (1) IL127715A (enExample)
NO (1) NO317754B1 (enExample)
NZ (1) NZ333586A (enExample)
PT (1) PT915697E (enExample)
RU (1) RU2214241C2 (enExample)
SK (1) SK284305B6 (enExample)
UA (1) UA53655C2 (enExample)
WO (1) WO1998000130A2 (enExample)
ZA (1) ZA975772B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CA2364949A1 (en) * 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
MXPA01010218A (es) 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
JP4709392B2 (ja) * 1999-04-08 2011-06-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
JP4825353B2 (ja) * 1999-04-08 2011-11-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血圧を下げることに有用な抗痙攣薬誘導体
CA2369230A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
PT1309324E (pt) * 2000-07-07 2006-06-30 Ortho Mcneil Pharm Inc Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
ATE334718T1 (de) * 2000-10-30 2006-08-15 Ortho Mcneil Pharm Inc Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
ATE474572T1 (de) * 2000-11-30 2010-08-15 Novodermix Internat Ltd Heilung von wunden
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4586916A (en) * 1985-01-30 1986-05-06 Consolidated Papers, Inc. Corrugated carton separator
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates

Also Published As

Publication number Publication date
CZ293876B6 (cs) 2004-08-18
EP0915697A2 (en) 1999-05-19
ATE224189T1 (de) 2002-10-15
UA53655C2 (uk) 2003-02-17
NO986052L (no) 1999-02-23
AU732923B2 (en) 2001-05-03
ZA975772B (en) 1998-12-28
US6071537A (en) 2000-06-06
WO1998000130A2 (en) 1998-01-08
RU2214241C2 (ru) 2003-10-20
WO1998000130A3 (en) 1998-02-12
AU3957897A (en) 1998-01-21
SK180598A3 (en) 2000-07-11
NO317754B1 (no) 2004-12-13
HK1018743A1 (en) 2000-01-07
JP2000514425A (ja) 2000-10-31
HUP0001192A3 (en) 2002-09-30
HUP0001192A2 (hu) 2000-11-28
BR9710994A (pt) 2000-10-24
CA2258893C (en) 2005-06-14
EP0915697B1 (en) 2002-09-18
CN1224352A (zh) 1999-07-28
IL127715A (en) 2004-07-25
NZ333586A (en) 2000-05-26
CA2258893A1 (en) 1998-01-08
AP9801429A0 (en) 1998-12-31
NO986052D0 (no) 1998-12-22
DE69715631D1 (de) 2002-10-24
IL127715A0 (en) 1999-10-28
SK284305B6 (sk) 2005-01-03
AP1285A (en) 2004-06-24
DE69715631T2 (de) 2003-05-08
ES2184127T3 (es) 2003-04-01
HU226775B1 (en) 2009-09-28
CN1106193C (zh) 2003-04-23
CZ427898A3 (cs) 1999-08-11
DK0915697T3 (da) 2003-01-27

Similar Documents

Publication Publication Date Title
PT915697E (pt) Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade
NO983266D0 (no) Distribuert Behandling
DK0951447T3 (da) Vandbehandling
DE69517659D1 (de) Verbinder
DE69618176D1 (de) Weiches behandeltes tissue
DE69634279D1 (de) Verbinder
DE69705170D1 (de) Verbinder
DE69533177D1 (de) Wasserbehandlungsvorrichtung
DE59701304D1 (de) Wirbelsäulenorthese
DE69602671D1 (de) Verbinder
FI955080A0 (fi) Vedenkäsittelyjärjestelmä
FI972484L (fi) Karsinooman hoito
DE69523489D1 (de) Verbinder
DE69521660D1 (de) Verbinder
DE59500113D1 (de) Aminofunktionelle Organopolysiloxane
DE59703238D1 (de) Vernetzbare organopolysiloxanmassen
NO983263L (no) Distribuert behandling
DE69723647D1 (de) Verbinder
DE69737872D1 (de) Verbinder
DE69705463D1 (de) Verbinder
DE69621746D1 (de) Verbinder
ITPD930192A1 (it) Vasca da bagno per idromassaggio, in particolare idromassaggio dorsale
BR9708159A (pt) Tratamento de cacau
DE69603897D1 (de) Verbinder
NO984906D0 (no) Vannbehandling